Au HKE,Isalan M,Mielcarek M M .2022 .Gene therapy advances: A meta-analysis of AAV usage in clinical settings. Front. Med, 8 : 809118.
Buck TM,Wijnholds J .2020 .Recombinant adenoassociated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays. Int. J. Mol. Sci, 21(12) : 4197.
Bulcha JT,Wang Y,Ma H,Tai PWL,Gao G .2021 .Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther., 6(1) : 53.
El Andari J,Grimm D J .2021 .Production, processing, and characterization of synthetic AAV gene therapy vectors. , 16(1) : 2000025.
Ghosh S,Brown AM,Jenkins C,Campbell K C .2020 .Viral vector systems for gene therapy: A comprehensive literature review of progress and biosafety challenges. Appl, 25(1) : 7-18.
Hacker UT,Bentler M,Kaniowska D,Morgan M,Büning H M .1889 .Towards clinical implementation of adeno-associated virus (AAV) vectors for cancer gene therapy: Current status and future perspectives. Cancers, 12(7) : .
Issa SS,Shaimardanova AA,Solovyeva VV,Rizvanov AA .2023 .Various AAV serotypes and their applications in gene therapy: An overview. Cells, 12(5) : 785.
Kishimoto TK,Samulski RJ .2022 .Addressing high dose AAV toxicity 'one and done'or 'slower and lower' ? Expert Opin. , 22(9) : 1067-1071.
Samulski RJ Li C .2020 .Engineering adenoassociated virus vectors for gene therapy. Nat. Rev. Genet, 21(4) : 255-272.
Mendell JR,Al-Zaidy SA,Rodino-Klapac LR,Goodspeed K,Gray SJ,Kay CN,Boye SL,Boye SE,George LA,Salabarria S,Corti M,Byrne BJ,Tremblay JP .2021 .Current clinical applications of in vivo gene therapy with AAVs. Mol. Ther, 29(2) : 464-488.
Nidetz NF,McGee MC,Tse LV,Li C,Cong L,Li Y,Huang W Y .2020 .Adeno-associated viral vectormediated immune responses: Understanding barriers to gene delivery. Pharmacol, 207 : 107453.
Pham Q,Glicksman J,Chatterjee A .2024 .Chemical approaches to probe and engineer AAV vectors. Nanoscale, 16(29) : 13820-13833.
Pupo A,Fernández A,Low SH,François A,SuárezAmarán L,Samulski RJ .2022 .AAV vectors: The Rubik's cube of human gene therapy. Mol. Ther, 30(12) : 3515-3541.
Ronzitti G,Gross DA,Mingozzi F DA .2020 .Human immune responses to adeno-associated virus (AAV) vectors. , 11 : 670.
Schmidt M,Foster GR,Coppens M,Thomsen H,Dolmetsch R,Heijink L,Monahan PE,Pipe SW PE .2023 .Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. , 7(17) : 4966-4969.
Shirley JL,de Jong YP,Terhorst C,Herzog RW C .2020 .Immune responses to viral gene therapy vectors. Mol. Ther, 28(3) : 709-722.
Sidonio RF,Pipe SW,Callaghan MU,Valentino LA,Monahan PE,Croteau SE .2021 .Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev., 47 : 100759.
Tran NT,Heiner C,Weber K,Weiand M,Wilmot D,Xie J,Wang D,Brown A,Manokaran S,Su Q,Zapp ML,Gao G,Tai PWL G .2020 .AAV-genome population sequencing of vectors packaging CRISPR components reveals design-influenced heterogeneity. Mol. Ther. Methods Clin. Dev, 18 : 639-651.
Wang Y,Bruggeman KF,Franks S,Gautam V,Hodgetts SI,Harvey AR,Williams RJ,Nisbet DR .2021 .Is viral vector gene delivery more effective using biomaterials? Adv. , 10(1) : 2001238.
Xu Q,Chen S,Hu Y,Huang W Y .2021 .Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front. Immunol., 12 : 711433.
Zhao H,Lee KJ,Daris M,Lin Y,Wolfe T,Sheng J,Plewa C,Wang S,Meisen WH .2020 .Creation of a highyield AAV vector production platform in suspension cells using a design-of-experiment approach. Mol. Ther. Methods Clin. Dev, 18 : 312-320.
Zhao Z,Anselmo AC,Mitragotri S AC .2022 .Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med, 7(1) : e10258.
Zu H,Gao D H .2021 .Non-viral vectors in gene therapy: Recent development, challenges and prospects. , 23(4) : 78.